Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced that George Magrath, M.D., Chief Executive Officer, will participate in a fireside chat during the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference, which will be available on demand on Wednesday, August 13, 2025 at 7:00 a.m. ET.

Read more at globenewswire.com